Entrada Therapeutics, Inc. (TRDA)

NASDAQ: TRDA · USD

$4.87

+0.46 (+10.4%)· Recorded snapshot

Market cap	175.6M
Revenue (ttm)	4.7M
Net income (ttm)	-165.8M
EPS (ttm)	-$3.97
Shares out	36.1M
Volume	344,986
Beta	-0.24

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 4.7M
Net income (ttm): -165.8M
EPS (ttm): -$3.97
Market cap: 175.6M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Mantener

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-54.1

P25 n/aP50 n/aP75 n/a

ROIC-280.1

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All TRDA indicators

Market & fundamental data

Available fields

194

Groups with data

Currency

USD

Showing 194 of 194 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001689375
Company name	Entrada Therapeutics, Inc.
Country	United States
Country code	US
CUSIP number	29384C108
Earnings date	2026-11-09
Earnings time	bmo
Employees	152
Employees change	-31
Employees growth	-16.94%
Enterprise value	$1.1M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2016
In index	RUSSELL2000
Industry	Biotechnology
IPO date	2021-10-29
Is primary listing	Yes
Is SPAC	No
ISIN number	US29384C1080
Last 10-K release date	2026-02-26
Last earnings date	2026-08-05
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$175.6M
Market cap category	Micro-Cap
Next earnings date	2026-11-09
Options	Yes
Price	$4.87
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	TRDA
U.S. state	Massachusetts
Website	https://www.entradatx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-81.47%
FCF / EV yield	869.6%
FCF yield	-84.49%
Forward P/S	4.88x
P/B ratio	0.68x
P/S ratio	33.93x
Price / tangible book value	0.68x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Operating margin	-3,726.53%
Pretax margin	-3,520.25%
Profit per employee	$-1.1M
Revenue per employee	$30,829
ROA	-29.2%
ROA (5Y)	-11.26%
ROCE	-62.93%
ROE	-54.09%
ROE (5Y)	-17.94%
ROIC	-280.08%
SBC / revenue	413.32%
Tax / revenue	17.48%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	1
EPS growth years	0
Net income growth quarters	1
Net income growth years	0
Revenue growth	-94.1%
Revenue growth (Q)	-53.95%
Revenue growth (QoQ)	2.63%
Revenue growth 3Y	-52.39%
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$323,000
Depreciation and amortization	$3.8M
EBIT	$-174.6M
EBITDA	$-170.9M
EPS	$-3.97
FCF per share	$-3.73
Financing cash flow	$650,000
Free cash flow	$-134.4M
Free cash flow minus SBC	$-153.7M
Gross profit	$-134.4M
Income taxes	$819,000
Investing cash flow	$160.2M
Net cash flow	$26.1M
Net income	$-165.8M
Operating cash flow minus SBC	$-154M
Operating income	$-174.6M
Revenue	$4.7M
Stock-based compensation	$19.4M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	0.16
Book value per share	$6.47
Debt / equity	0.21
Long-term assets	$66.2M
Long-term liabilities	$44.1M
Net cash (debt)	$174.5M
Net cash / market cap	109.72%
Net cash growth	-41.7%
Net debt / equity	-0.75
Piotroski F-Score	1
Property, plant and equipment	$62.8M
Shareholders' equity	$233.4M
Tangible book value	$233.4M
Tangible book value per share	$6.47
Total assets	$298.9M
Total cash	$223M
Total debt	$48.5M
Total liabilities	$65.5M
WACC	2.25%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.01
Current assets	$232.7M
Current liabilities	$21.4M
Current ratio	10.89
Net working capital	$-7.2M
Quick ratio	10.52
Working capital	$211.3M
Working capital turnover	0.02

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-1.93%
Dividend yield	0%
Shareholder yield	-1.93%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$7.92
1D price change	10.43%
1M price change	-22.32%
1M total return	-22.32%
1W price change	-4.11%
1W total return	-4.11%
1Y price change	-34.54%
1Y return CAGR	-34.56%
1Y total return	-34.54%
20-day SMA	$5.02
200-day SMA	$8.83
3M price change	-21.3%
3M total return	-21.3%
3Y price change	-67%
3Y return CAGR	-30.89%
3Y total return	-67%
50-day SMA	$6.17
50-day SMA vs 200-day SMA	50under200
52-week high	$16.45
52-week high date	2026-05-06
52-week low	$4.11
52-week low date	2026-10-14
6M price change	-63.08%
6M total return	-63.08%
All-time high	$36.85
All-time high date	2021-11-18
All-time low	$4.11
All-time low date	2026-10-14
Average true range (ATR)	$0.46
Average volume	393.8K
Beta (1Y)	-0
Beta (2Y)	1.01
Beta (5Y)	-0.24
Change from 52-week high	-70.4%
Change from 52-week low	18.52%
Change from all-time high	-87.01%
Change from all-time low	16.45%
Change from open	11.19%
Day's gap	-0.68%
Dollar volume	$1.7M
High price	$4.87
Low price	$4.38
Monthly RSI	36.26
Open price	$4.38
Position in 52-week range	100%
Premarket change	5.44%
Premarket close	$4.41
Premarket price	$4.65
Premarket volume	300
Previous close	$4.41
Price vs 150-day SMA	-39.55%
Price vs 20-day SMA	-4.66%
Price vs 200-day SMA	-45.81%
Price vs 50-day SMA	-22.49%
Relative volume	0.88
Return from IPO open	-83.36%
Return from IPO price	-77.95%
RSI	42.62
Sharpe ratio	0.04
Sharpe ratio (3Y)	-0.15
Sortino ratio	0.1
Sortino ratio (3Y)	-0.12
Volume	345K
Weekly RSI	36.39
YTD price change	-53.45%
YTD total return	-53.45%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	22.7M
Float percentage	62.87%
Shares change (QoQ)	0.92%
Shares change (YoY)	1.93%
Shares held by insiders	1.79%
Shares held by institutions	52.54%
Shares outstanding	36.1M
Short % of float	13.19%
Short % of shares	8.29%
Short ratio	9 days

Deeper analysis on TRDA

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this TRDA report

Is a complete TRDA research report available?

No complete published report is available for Entrada Therapeutics, Inc. (TRDA) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Entrada Therapeutics, Inc. (TRDA)

Price

Financial snapshot

Fair-value bridge

Latest news · TRDA

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All TRDA indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on TRDA

Frequently asked questions